Atrial Fibrillation and Cancer

Area of Science:

• Oncology
• Cardiology
• Immunology

Background:

• Cancer patients exhibit elevated risk for atrial fibrillation (AF) compared to the general population.
• Pro-inflammatory status and heightened inflammatory responses to cancer treatments and surgeries contribute to AF development in these patients.

Purpose of the Study:

• To elucidate the pathophysiological mechanisms linking cancer and AF.
• To identify therapeutic challenges in managing AF within the cancer patient population.
• To highlight the unmet need for validated risk prediction scores for thromboembolic and bleeding events in cancer-related AF.

Main Methods:

• This review synthesizes current literature on the mechanisms of AF in cancer patients.
• It examines the limitations of existing stroke and bleeding risk prediction scores (e.g., CHA2DS2-VASc, HAS-BLED) in this specific cohort.
• The review discusses the inflammatory pathways involved in cancer-associated AF.

Main Results:

• Inflammation is a key driver of AF in cancer patients.
• Standard risk scores are not adequately validated for cancer patients, posing challenges in anticoagulation and management decisions.
• Cancer treatment and surgical interventions exacerbate AF risk.

Conclusions:

• Understanding the unique mechanisms of AF in cancer is crucial for effective management.
• Development of validated risk stratification tools is essential for optimizing anticoagulation and reducing morbidity/mortality.
• Addressing therapeutic challenges is paramount for improving outcomes in cancer patients with AF.